Form 8-K · Current report
Dexcom 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0001093557
- Accession no.
- 0001093557-26-000142
Summary
Dexcom reported second-quarter 2026 revenue of $1.308 billion, up 13% year over year, and GAAP net income of $249.1 million, or $0.64 per diluted share, while raising the midpoint of its full-year 2026 revenue guidance to $5.18–$5.25 billion. The company said its CONNECT randomized controlled trial showed clinically meaningful, statistically significant improvements in glucose control with Dexcom CGM use among people with type 2 diabetes not using insulin, and president and CEO Jake Leach said the quarter's performance and trial results reinforce confidence in its long-range plan.
Key points
- Quarterly revenue rose 13% year over year to $1.308 billion, with U.S. revenue up 11% and international revenue up 19%.
- GAAP operating income was $318.3 million, or 24.3% of revenue, up 590 basis points from the second quarter of 2025; GAAP net income was $249.1 million, or $0.64 per diluted share.
- Full-year 2026 guidance was raised to $5.18–$5.25 billion in revenue, about 64% non-GAAP gross margin, 23.5–24% non-GAAP operating margin, and 31.5–32% adjusted EBITDA margin.
- Dexcom held $1.95 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, with its revolving credit facility undrawn.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 30, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.